BridgeBio Pharma (BBIO) Stock Price, News, Quotes-Moomoo

Account Info

Log Out

US Stock MarketDetailed Quotes

BBIO BridgeBio Pharma

Watchlist

23.240
+0.200+0.87%

Close Nov 21 16:00 ET

23.240
0.0000.00%

Post 16:20 ET

4.39BMarket Cap-9603P/E (TTM)

Post-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

BridgeBio Pharma Call Volume Above Normal and Directionally Bullish
TipRanks14:30 ET
J.P. Morgan Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Cuts Target Price to $40
Moomoo NewsNov 21 07:34 ET · Ratings
Insider Sale: Secretary of $BBIO (BBIO) Sells 4,156 Shares
Quiver QuantitativeNov 20 20:01 ET
Express News | BridgeBio Pharma Inc : JP Morgan Cuts Target Price to $40 From $43
ReutersNov 20 00:58 ET
BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market
BenzingaNov 19 14:44 ET
Scotiabank Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $45
Moomoo NewsNov 19 08:32 ET · Ratings

Comments

Stock_Drift

Feb 2 04:12

$AstraZeneca (AZN.US)$ $BridgeBio Pharma (BBIO.US)$ $ASTRAZENECA PLC (AZNCF.US)$
📊⚡️📊

AstraZeneca's Results From Japan Phase 3 Trial Of Acoramidis For Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) Is Consistent With BridgeBio Pharma's ATTRibute-CM Phase 3 Trial, Including Survival, Cardiac-Related Hospitalizations

Movers and Shakers

Jan 31 07:07

Columns Today's Morning Movers and Top Ratings: GOOGL, AMD, TSLA, SBUX and More

Morning Movers
Gapping up
$Starbucks (SBUX.US)$ stock rose 3.7% after the coffee chain cut its annual sales forecast, warning of softer demand in January and a slow recovery in China. However, even more weakness had been expected following disappointing store traffic in November and December.
$Novo-Nordisk A/S (NVO.US)$ stock rose 0.5% after the Danish drugmaker forecast another year of double-digit growth due to the populari...

Analysts Notebook

Dec 27, 2023 04:18

Columns Biotech Outlook 2024: Analysts Believe the Biotech Sector is Poised for Recovery Next Year

Following a turbulent period, there has been a notable change in the trajectory of biotech stocks. After experiencing significant downturns in 2021 and 2022, the $SPDR S&P Biotech ETF (XBI.US)$ has seen an increase of 5.5% in the current year. However, it continues to trail considerably behind the $S&P 500 Index (.SPX.US)$, which has achieved a 24% gain. However, analysts indicate that the previously cool sent...

Trytosaveabit

Nov 9, 2023 06:32

Update

$BridgeBio Pharma (BBIO.US)$ BridgeBio Pharma to Present Additional Data from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the American Heart Association (AHA) Scientific Sessions 2023
2 MINUTES AGO, 7:30 AM EST
VIA GLOBENEWSWIRE